FDA Warns of Increased Risk of Death with Tygacil Use
The FDA has issued a black box warning for Pfizer’s antibacterial drug Tygacil due to an increased risk of death associated with the use of this intravenous medication. Tygacil is used to treat patients with complicated skin and skin structure infections (cSSSI), complicated intra-abdominal infections (cIAI), and community-acquired bacterial pneumonia (CABP). Serious side effects may include irregular heartbeat, severe stomach and abdominal pain, blurred vision, and severe diarrhea which can occur weeks after treatment.
The FDA analyzed data from 10 clinical trials and found a higher risk of death among patients receiving Tygacil compared to other antibacterial drugs. This safety communication includes instruction to healthcare providers stating that Tygacil should only be used in situations when alternative treatments are not suitable. More information about this warning can be found on the FDA website.
If you or someone you care about has been prescribed Tygacil and suffered a serious injury, contact us. Our product liability attorneys have litigated thousands of product liability claims against pharmaceutical companies and medical device manufacturers and can advise you of your legal rights and options.
